Barcelona, 11th September, 2017 – The Optogenerapy consortium will be gathered together for its second meeting after the project’s kick-off in February. The meeting, hosted by the project’s partner ETHZ, the Swiss Federal Institute of Technology Zurich, will take place in Basel on September 14th and 15th.
The first six months of the project have been busy in defining specifications and designing the first pieces of the Optogenerapy solution that will conform the implant device. The pieces developed will be integrated together in the following months, but functionality and biological viability tests can start soon.
The meeting aims at reviewing the advances in the different developments of the elements composing the device in the framework of the different work packages, and plan and prepare upcoming milestones and tasks.
Among the upcoming tasks to be discussed by the consortium during the meeting, partners will plan a first round of individual interviews with neurologists specialized in Multiple Sclerosis in order to get valuable feedback on the new Optogenerapy device and assure that the novel implant meet and is aligned with clinicians needs.